<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585545</url>
  </required_header>
  <id_info>
    <org_study_id>2012-03-068</org_study_id>
    <nct_id>NCT01585545</nct_id>
  </id_info>
  <brief_title>Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers</brief_title>
  <official_title>Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate relationships between multiparametric imaging
      biomarkers and genetic analysis in NSCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate relationships between multiparametric imaging biomarkers(CT, PET/CT, MRI) and
      genetic analysis in NSCLC patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional and genomic profiling of lung cancer</measure>
    <time_frame>five years</time_frame>
    <description>Prognostic stratification will be evaluated using following parameters:
Quantitative and qualitative parameters from CT, PET, MRI
Genomic data of lung cancer samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between genomic and multiparametric imaging profiling</measure>
    <time_frame>five years</time_frame>
    <description>We will evaluate if certain relationship exists between changes in multiparametric imaging markers from CT, PET, MRI and genomic informations of NSCLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precise prediction of pulmonary function such as ventilation and perfusion after the lung resection.</measure>
    <time_frame>five years</time_frame>
    <description>following parameters exracted from whole lung will be evaluated: Quantitative parameters related to pulmonary function from CT, PET, MRI 2. Prediction of longitudinal changes of pulmonary function after the lung resection</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>patients with NSCLC</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      lung cance tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with non-small cell lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected lung cancer on chest CT or histologically proven NSCLC

          -  Participant is being considered for the conventional/neoadjuvant/targeted chemotherapy
             or surgery

          -  At least one measurable primary or other intrathoracic lesion &gt;= 2cm, according to
             RECIST

          -  Performance status of 0 to 2 on the ECOG scale

          -  Age 20 years or older

          -  Able to tolerable PET/CT and CT imaging required by protocol

          -  Able to undergo percutaneous needle biopsy before and after chemotherapy

          -  Able to give study-specific informed consent

        Exclusion Criteria:

          -  Poorly controlled diabetes

          -  Contraindication for CT contrast agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Yun Lee, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho Yun Lee, Dr</last_name>
    <phone>82-2-3410-2502</phone>
    <phone_ext>82-2-3410-2502</phone_ext>
    <email>hoyunlee96@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Yun Lee, Dr.</last_name>
      <phone>82-2-3410-2502</phone>
      <phone_ext>82-2-3410-2502</phone_ext>
      <email>hoyunlee96@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ho Yun Lee, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Yun Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>CT</keyword>
  <keyword>PET CT</keyword>
  <keyword>MRI</keyword>
  <keyword>cancer genomics</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Radiogenomics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

